These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28255985)

  • 21. Novel HPD mutation p.A244V compound with p.T219M causing tyrosinemia type III in a Chinese girl and review of the genotype-phenotype spectrum.
    Han D; Wang L; Zhao C; Li J; Huang C; Song W; Wang H; Li X; Tao Y
    Mol Genet Genomic Med; 2024 Jan; 12(1):e2298. PubMed ID: 37817461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
    Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
    J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of DNAI1 in primary ciliary dyskinesia: evidence of founder effect in a common mutation.
    Zariwala MA; Leigh MW; Ceppa F; Kennedy MP; Noone PG; Carson JL; Hazucha MJ; Lori A; Horvath J; Olbrich H; Loges NT; Bridoux AM; Pennarun G; Duriez B; Escudier E; Mitchison HM; Chodhari R; Chung EM; Morgan LC; de Iongh RU; Rutland J; Pradal U; Omran H; Amselem S; Knowles MR
    Am J Respir Crit Care Med; 2006 Oct; 174(8):858-66. PubMed ID: 16858015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III.
    Rüetschi U; Cerone R; Pérez-Cerda C; Schiaffino MC; Standing S; Ugarte M; Holme E
    Hum Genet; 2000 Jun; 106(6):654-62. PubMed ID: 10942115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong.
    Mak CM; Lam CW; Chim S; Siu TS; Ng KF; Tam S
    Clin Biochem; 2013 Jan; 46(1-2):155-9. PubMed ID: 23000314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Herpetiform keratitis and palmoplantar hyperkeratosis: warning signs for Richner-Hanhart syndrome.
    Soares DC; Stroparo MN; Lian YC; Takakura CY; Wolf S; Betz R; Kim CA
    J Inherit Metab Dis; 2017 May; 40(3):461-462. PubMed ID: 27832414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Richner-Hanhart syndrome (tyrosinemia II): early diagnosis of an incomplete presentation with unusual findings.
    Viglizzo GM; Occella C; Bleidl D; Rongioletti F
    Pediatr Dermatol; 2006; 23(3):259-61. PubMed ID: 16780475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients.
    Arranz JA; Piñol F; Kozak L; Pérez-Cerdá C; Cormand B; Ugarte M; Riudor E
    Hum Mutat; 2002 Sep; 20(3):180-8. PubMed ID: 12203990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Two cases of Richner-Hanhart syndrome (oculocutaneous tyrosinemia)].
    Bygum A; Brandrup F; Gade EF; Lund AM; Christensen E
    Ugeskr Laeger; 2008 Feb; 170(8):655. PubMed ID: 18364160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A founder ectodysplasin A receptor (EDAR) mutation results in a high frequency of the autosomal recessive form of hypohidrotic ectodermal dysplasia in India.
    Bashyam MD; Chaudhary AK; Reddy EC; Reddy V; Acharya V; Nagarajaram HA; Devi AR; Bashyam L; Dalal AB; Gupta N; Kabra M; Agarwal M; Phadke SR; Tainwala R; Kumar R; Hariharan SV
    Br J Dermatol; 2012 Apr; 166(4):819-29. PubMed ID: 22032522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Richner-Hanhart syndrome (tyrosinemia type II). Case report and literature review.
    al-Hemidan AI; al-Hazzaa SA
    Ophthalmic Genet; 1995 Mar; 16(1):21-6. PubMed ID: 7648039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
    Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
    Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Four mutations (three novel, one founder) in TACSTD2 among Iranian GDLD patients.
    Alavi A; Elahi E; Tehrani MH; Amoli FA; Javadi MA; Rafati N; Chiani M; Banihosseini SS; Bayat B; Kalhor R; Amini SS
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4490-7. PubMed ID: 17898270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin.
    Imtiaz F; Rashed MS; Al-Mubarak B; Allam R; El-Karaksy H; Al-Hassnan Z; Al-Owain M; Al-Zaidan H; Rahbeeni Z; Qari A; Meyer BF; Al-Sayed M
    Mol Genet Metab; 2011 Dec; 104(4):688-90. PubMed ID: 21764616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I.
    Elpeleg ON; Shaag A; Holme E; Zughayar G; Ronen S; Fisher D; Hurvitz H
    Hum Mutat; 2002 Jan; 19(1):80-1. PubMed ID: 11754109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosinemia Type III detected via neonatal screening: management and outcome.
    Heylen E; Scherer G; Vincent MF; Marie S; Fischer J; Nassogne MC
    Mol Genet Metab; 2012 Nov; 107(3):605-7. PubMed ID: 23036342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of a founder c.201_202delCT mutation and new phenotypic features of congenital lipoid adrenal hyperplasia in Palestinians.
    Abdulhadi-Atwan M; Jean A; Chung WK; Meir K; Ben Neriah Z; Stratigopoulos G; Oberfield SE; Fennoy I; Hirsch HJ; Bhangoo A; Ten S; Lerer I; Zangen DH
    J Clin Endocrinol Metab; 2007 Oct; 92(10):4000-8. PubMed ID: 17666473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of two new mutations in the TAT gene in a Danish family with tyrosinaemia type II.
    Pasternack SM; Betz RC; Brandrup F; Gade EF; Clemmensen O; Lund AM; Christensen E; Bygum A
    Br J Dermatol; 2009 Mar; 160(3):704-6. PubMed ID: 18945316
    [No Abstract]   [Full Text] [Related]  

  • 40. Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria.
    Tomoeda K; Awata H; Matsuura T; Matsuda I; Ploechl E; Milovac T; Boneh A; Scott CR; Danks DM; Endo F
    Mol Genet Metab; 2000 Nov; 71(3):506-10. PubMed ID: 11073718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.